Bradanicline - Attenua

Drug Profile

Bradanicline - Attenua

Alternative Names: ATA 101; TC-0569; TC-5619; TC-5619-238

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targacept
  • Developer Attenua; Targacept
  • Class Amides; Azabicyclo compounds; Benzofurans; Nootropics; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cough
  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders

Most Recent Events

  • 11 Sep 2017 Attenua plans a phase II proof of concept trial for Cough in November 2018 (PO) (NCT03622216)
  • 11 Sep 2017 Preclinical trials in Cough in USA (PO)
  • 02 Aug 2016 Catalyst Biosciences enters into a definitive agreement with Attenua for the divestiture of its neuronal nicotinic receptors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top